This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wilkinson, I. B. Articles by Filigheddu, F. Search for Related Content PubMed PubMed Citation Articles by Wilkinson, I. B. Articles by Filigheddu, F.

(Hypertension. 2000;36:e1.)
© 2000 American Heart Association, Inc.

Letters to the Editor

Pravastatin, Blood Pressure, and Stroke

Ian B. Wilkinson; John R. Cockcroft

Department of Medical Sciences, University of Edinburgh, Western General Hospital, Edinburgh, UK, Department of Cardiology, Wales Heart Research Institute, University Hospital, Cardiff, UK

	Introduction

 
To the Editor:

We read with interest the recent paper in Hypertension by Glorioso et al¹ demonstrating that the HMG-CoA reductase inhibitor pravastatin significantly lowers blood pressure in patients with coexisting essential hypertension and primary hypercholesterolemia. This is an important finding that may, in part, explain the significant reduction in stroke observed in both the CARE² and LIPID³ studies, as previously suggested.⁴

Although epidemiological observations do not suggest any relationship between serum cholesterol and stroke,⁵ several studies have reported a positive correlation between blood pressure and cholesterol.⁶ Moreover, indirect evidence from several trials investigating cholesterol-lowering regimens suggests that lowering cholesterol may reduce blood pressure by between 2 and 5 mm Hg.⁶ Although such an effect is small, it is similar to the reduction in diastolic blood pressure of 5 mm Hg observed by Glorioso et al and, if sustained for 5 years, would be expected to reduce the incidence of stroke by 34%.⁷ Therefore, we believe that the 31% and 19% reduction in stroke reported in the CARE and LIPID studies, respectively, may be, in part, attributable to a blood pressure–lowering effect of pravastatin although, unfortunately, changes in blood pressure were not recorded in either trial.

One inconsistency in this argument is that some studies have failed to show any effect of pravastatin on blood pressure, as discussed by Glorioso et al, who suggest that, as with traditional antihypertensive agents, statins may only reduce blood pressure in hypertensive individuals and not normotensive subjects. They go on to speculate that any . . . [Full Text of this Article]

Nicola Glorioso; Fabiana Filigheddu

University of Sassari Medical School, Clinica Medica, Sassari, Italy \.